Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Phibro Animal Health Corporation (NASDAQ:PAHC) has received a consensus rating of "Hold" from eight brokerages, with varying price targets ranging from $19 to $34.
• The company recently reported earnings of $0.57 per share, exceeding estimates, and announced a quarterly dividend of $0.12 per share, resulting in a 1.2% dividend yield.
• Insider trading activity showed CEO Jack Bendheim sold 7,022 shares at an average price of $40.26, reducing his ownership by 18.31%.

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) have been assigned an average rating of "Hold" from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $28.40.

Several research analysts have issued reports on the stock. Bank of America raised their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the stock an "underperform" rating in a research report on Friday, August 29th. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a research report on Thursday, August 28th. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $25.00 to $35.00 in a report on Monday, July 7th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Phibro Animal Health in a report on Tuesday, October 14th. Finally, Zacks Research raised shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Monday, September 29th.

Phibro Animal Health Trading Up 3.0%

Shares of Phibro Animal Health stock opened at $39.72 on Friday. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $41.57. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The company has a market capitalization of $1.61 billion, a P/E ratio of 33.66, a PEG ratio of 1.20 and a beta of 0.83. The company's fifty day moving average is $36.78 and its two-hundred day moving average is $28.36.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The company had revenue of $378.70 million for the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd were issued a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, September 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health's payout ratio is presently 40.68%.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,022 shares of Phibro Animal Health stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $40.26, for a total value of $282,705.72. Following the sale, the chief executive officer owned 31,338 shares of the company's stock, valued at $1,261,667.88. The trade was a 18.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 24,622 shares of company stock valued at $995,893 over the last quarter. 50.13% of the stock is owned by insiders.

Institutional Trading of Phibro Animal Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Phibro Animal Health by 0.4% during the first quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company's stock worth $32,500,000 after buying an additional 6,784 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Phibro Animal Health by 0.5% during the first quarter. Acadian Asset Management LLC now owns 782,939 shares of the company's stock worth $16,713,000 after buying an additional 4,144 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Phibro Animal Health by 1.4% during the second quarter. Geode Capital Management LLC now owns 554,927 shares of the company's stock worth $14,175,000 after buying an additional 7,841 shares in the last quarter. Nuveen LLC purchased a new stake in Phibro Animal Health during the first quarter worth about $10,312,000. Finally, Invesco Ltd. boosted its holdings in Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company's stock worth $8,282,000 after buying an additional 186,087 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.